U.S. Electronic Equipment and Components Stock News

NasdaqGS:SOFI
NasdaqGS:SOFIConsumer Finance

Latest News In Digital Payment - RemitBee Partners With Visa For Global Payment Expansion

In a recent development in the realm of digital payments, RemitBee Inc., a Canadian fintech platform, has announced a collaboration with Visa Canada to enhance cross-border payment services. By integrating with Visa Direct, RemitBee aims to provide faster and more secure international transfers to over 190 countries, addressing common issues faced by Canada's immigrant community in sending money abroad. This collaboration not only signifies an important milestone for Canada's domestic fintech...
NYSE:FIGS
NYSE:FIGSLuxury

Why FIGS (FIGS) Is Down 16.8% After Raising 2026 Revenue Guidance on Strong Q1 Results

In the first quarter of 2026, FIGS, Inc. reported net revenue of US$159.9 million, up from US$124.9 million a year earlier, and moved from a small net loss to net income of US$6.29 million, with basic earnings per share of US$0.04. The company’s strong quarter was underpinned by 28% year-over-year net revenue growth, passing three million active customers and prompting management to raise full-year 2026 revenue guidance to 14%–16% growth, even as this implied slower growth than the first...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Does FDA Review Of Ulixacaltamide And Relutrigine Reshape The Bull Case For Praxis (PRAX)?

In early May 2026, Praxis Precision Medicines reported a first-quarter net loss of US$92.56 million, while also securing FDA acceptance of new drug applications for ulixacaltamide in essential tremor and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies. Alongside these filings, Praxis highlighted positive early-stage data for elsunersen showing a very large placebo-adjusted seizure reduction in SCN2A-DEE, underscoring growing clinical momentum across its central...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

How Strong Q3 Beat and Raised Outlook Will Impact Affirm Holdings (AFRM) Investors

In early May 2026, Affirm Holdings reported fiscal third-quarter results showing revenue of US$1.04 billion and net income of US$102.9 million, both above the prior year and ahead of analyst expectations, and raised its full-year outlook. Beyond the headline beat, Affirm highlighted robust growth in gross merchandise volume and active consumers, suggesting its expanding merchant network and card offering are gaining traction across more frequent, everyday transactions. With this strong...
NYSE:WU
NYSE:WUDiversified Financial

Should Western Union’s New USDPT Stablecoin Strategy Reshape Expectations For WU Investors?

In early May 2026, Western Union launched USDPT, a fully U.S. dollar-backed stablecoin issued by Anchorage Digital Bank N.A. on the Solana blockchain and integrated into its global payment and compliance infrastructure for uses ranging from exchange access to near-instant agent settlement. This move signals Western Union’s push to embed regulated digital assets into everyday remittances and cash-based payments, potentially reshaping how customers move and access digital dollars...
NYSE:AXP
NYSE:AXPConsumer Finance

American Express (AXP) Valuation Check After Q1 2026 Growth And Business Travel Exit Plan

American Express (AXP) shares have been moving against a backdrop of firm Q1 2026 results, a planned exit from its remaining Global Business Travel stake, and clear backing for management at the recent annual shareholder meeting. See our latest analysis for American Express. The recent Q1 update, preferred dividend declaration, and shareholder backing have come against a choppy share price backdrop. The stock is down 15.21% on a year to date share price basis but supported by a 6.83% 1 year...
NasdaqGS:TNYA
NasdaqGS:TNYABiotechs

Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts

Tenaya Therapeutics, Inc. recently reported a reduced net loss of US$19.27 million for the first quarter of 2026 and secured multiple scientific presentations, including new RIDGE-1 Phase 1b/2 data for its investigational TN-401 gene therapy in PKP2-associated arrhythmogenic right ventricular cardiomyopathy, now scheduled in the coming days at the ASGCT Annual Meeting 2026. These events, alongside company participation at Heart Failure 2026 and renewed analyst confidence, spotlight Tenaya’s...